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A recent paper in Malaria Journal suggests that a high proportion of Plasmodium falciparum isolates found in
travellers returning from a range of African countries carry the PfATP6 A623E S769N haplotype, and that this
genotype is associated with artemether resistance. Such a finding would represent a substantial departure from the
extensive literature reporting these individual mutations to be very rare, with the double mutation never
documented. The number of isolates screened to obtain these double mutants is unstated, but highly relevant, not
least because selection of isolates could have introduced significant confounders, such as timing of in vitro testing.
An additional concern relates to the location of sequencing primers used to assess these positions. In the absence
of clear information on these fundamental questions it would be appropriate to treat the findings with caution.Pillai et al. [1] describe a possible association between the
PfATP6 A623E S769N haplotype and artemether resistance
in Plasmodium falciparum isolates in returning travellers
from eight African countries. A large number of studies
have been undertaken specifically to look for these and
other polymorphisms at a global level, both before and after
the introduction of artemisinin combination therapy. As
the authors point out, A623E and S769N have never been
reported in the same isolate, and even as separate entities
they have only been found at very low prevalence in a small
number of countries. Among approximately 1,000 samples
studied originating in the eight countries described in the
report, only two isolates have been found with the A623E
mutation (in Tanzania) and no isolate has been found with
the S769N mutation [2-10] (Table 1).
The finding of A623E S769N double mutants in 11 of
28 patients in one centre is, therefore, highly unex-
pected. The authors propose that natural selection for
these polymorphisms may be taking place in the coun-
tries of origin for these parasites, because of the rapid
scale up of anti-malarial treatment programmes being
implemented in recent years. However, before natural
selection is invoked, a much more basic concern needs* Correspondence: charlie@tropmedres.ac
1Mahidol-Oxford University Tropical Medicine Research Unit (MORU),
Bangkok, Thailand
Full list of author information is available at the end of the article
© 2012 Woodrow et al.; license Biomed Centr
Commons Attribution License (http://creativec
reproduction in any medium, provided the orto be addressed, namely selection of isolates in the la-
boratory. It is notable that the median date of receipt for
the mutant isolates was around 500 days before that of
the wild-type samples (according to the supplementary
data). This is of profound methodological importance
since use of wild-type controls with different properties
to the mutant population (such as date of assay) would
introduce a significant confounder. How many isolates
were screened to obtain the final 11 double mutants?
And how were the wild-type controls selected?
Another possible explanation for the high reported fre-
quency of mutant haplotypes relates to the methods
used to sequence the PfATP6 gene itself. Examination of
the sequencing primers appears to indicate that the for-
ward biotinylated primer reported by the authors to have
been used to assess the A623E polymorphism lies over
the A623 position itself (Figure 1). Since primer is incor-
porated into product, it is difficult to understand how
position 623 was assessed, and specifically how A623E
mutants could have been seen at all.
In the absence of clear information on these funda-
mental questions it would be appropriate to treat the
findings and conclusions of the article with caution.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Location of the forward biotinylated primer used to assess the A623E polymorphism in the PfATP6 coding sequence. The
primer lies over the A623 position itself.
Table 1 Previous publications on prevalence of the A623E and S769N polymorphisms in the countries described by
Pillai et al. [1]
A623E Reference S769N Reference
Nigeria 0/11 [3] 0/11 [3]
Ghana 0/120 [3] (0/13), [4] (0/1), [7] (0/38), [9] (0/68) 0/120 [3] (0/13), [4] (0/1), [7] (0/38), [9] (0/68)
Angola 0/76 [3] (0/10), [6] (0/66) 0/76 [3] (0/10), [6] (0/66)
Cameroon 0/160 [3] (0/2), [5] (0/97), [8] 0/61 0/160 [3] (0/2), [5] (0/97), [8] 0/61
Tanzania 2/636 [2] (0/288), [4] 2/279, [7] 0/69, 0/635 [2] (0/197), [4] 0/279, [7] 0/69, [10] 0/90
Liberia 0/1 [4] 0/1 [4]
Kenya 0/4 [3] 0/4 [3]
Total 2/1008 0/1007
The data indicate numbers of samples with mutation/number of samples assayed. In cases where the precise number of samples examined for each SNP was not
reported the lowest possible number within the range described is shown.
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